|
41 Companies |
|
50 Products |
|
50 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
299 News |
|
| «123456» |
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Trial termination, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2014
P1, N=4, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Negative data from another trial led to termination of this trial by sponsor.
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Enrollment change, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2014
P1, N=4, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Negative data from another trial led to termination of this trial by sponsor. N=20 --> 4
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
New P1/2 trial, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=41, Not yet recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
- | Orencia (abatacept) / BMS
New P2 trial, P2 data: Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study (clinicaltrials.gov) - Jan 2, 2014
P2, N=15, Recruiting, Sponsor: Qingping Yao
- Trial completion: Xylitol Disk Use in Adults With Dry Mouth (clinicaltrials.gov) - Nov 30, 2013
P=N/A, N=7, Completed, Sponsor: University of Washington
N=20 --> 4 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: MAESTRO HN: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (clinicaltrials.gov) - Nov 24, 2013
P2, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- Clinical data, Trial completion, Surgery: Retrospective Clinical Outcome of Parotid Tumor Surgery (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=767, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| New P3 trial: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (clinicaltrials.gov) - Nov 7, 2013
P3, N=1560, Not yet recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Enrollment open: Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=32, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) - Oct 17, 2013
P1/2, N=30, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- hydroxychloroquine / Generic mfg.
Enrollment change: Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - Oct 15, 2013
P3, N=39, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting N=60 --> 39
- hydroxychloroquine / Generic mfg.
Trial completion: Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - Oct 15, 2013
P3, N=39, Completed, Sponsor: Seoul National University Hospital
N=60 --> 39 Recruiting --> Completed
- Trial withdrawal: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=3000 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, sunitinib / Generic mfg.
Trial termination, Metastases: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
N=3000 --> 0 Active, not recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, sunitinib / Generic mfg.
Trial initiation date, Metastases: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Initiation date: Jul 2007 --> Jul 2008
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy, Metastases: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (clinicaltrials.gov) - Jun 30, 2013
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2007 --> Jul 2008 Active, not recruiting --> Completed
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Enrollment change, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Jun 13, 2013
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed N=80 --> 18
- || New P3 trial: Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) (clinicaltrials.gov) - Jun 9, 2013
P3, N=150, Completed, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- lapatinib / Generic mfg.
Trial completion, Metastases: Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jun 2, 2013
P2, N=30, Completed, Sponsor: National Cancer Institute (NCI)
N=80 --> 18 Suspended --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - May 28, 2013
P1, N=13, Recruiting, Sponsor: University of Washington
Suspended --> Completed N=18 --> 13
- | Enrollment open: Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer (clinicaltrials.gov) - May 19, 2013
P3, N=240, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=18 --> 13 Not yet recruiting --> Recruiting
- | Trial completion: Proof-of-concept (PoC) Study of APD515 (clinicaltrials.gov) - May 14, 2013
P2, N=32, Completed, Sponsor: Acacia Pharma Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed
- New P4 trial: Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops (clinicaltrials.gov) - May 8, 2013
P4, N=24, Completed, Sponsor: University of Sao Paulo General Hospital
- ispinesib (SB-715992) / Cytokinetics
Enrollment change, Metastases: SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - May 6, 2013
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=21 --> 33
- lapatinib / Generic mfg.
Enrollment change, Metastases: Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers (clinicaltrials.gov) - May 6, 2013
P2, N=67, Completed, Sponsor: National Cancer Institute (NCI)
N=21 --> 33 N=40 --> 67
- erlotinib / Generic mfg.
Enrollment closed: Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung (clinicaltrials.gov) - Apr 30, 2013
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 67 Recruiting --> Active, not recruiting
- | tropicamide / Generic mfg.
New P2 trial: Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients (clinicaltrials.gov) - Apr 29, 2013
P2, N=36, Recruiting, Sponsor: NeuroHealing Pharmaceuticals Inc.
- Trial completion: A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children (clinicaltrials.gov) - Apr 25, 2013
P1, N=300, Completed, Sponsor: Chinese Academy of Medical Sciences
Recruiting --> Active, not recruiting Recruiting --> Completed
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial completion, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Apr 22, 2013
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- dasatinib / Generic mfg.
Trial termination, Metastases: Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 21, 2013
P2, N=15, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Enrollment change, IO biomarker: Neuro-SGSp: Neurotrophins Implications in Primary Sj (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=40, Completed, Sponsor: University Hospital, Limoges
Completed --> Terminated N=80 --> 40
- Trial completion, IO biomarker: Neuro-SGSp: Neurotrophins Implications in Primary Sj (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=40, Completed, Sponsor: University Hospital, Limoges
N=80 --> 40 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial initiation date, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 8, 2013
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Initiation date: Feb 2007 --> Jun 2007
- ||||||| Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
Trial completion: Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers (clinicaltrials.gov) - Mar 27, 2013
P3, N=542, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Initiation date: Feb 2007 --> Jun 2007 Active, not recruiting --> Completed
- Recentin (cediranib) / AstraZeneca
Enrollment closed, Monotherapy, Metastases: Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 25, 2013
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cisplatin / Generic mfg.
Enrollment open, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Mar 10, 2013
P1, N=15, Recruiting, Sponsor: Virginia Commonwealth University
Recruiting --> Active, not recruiting Suspended --> Recruiting
- Trial initiation date: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Initiation date: Jan 2013 --> Aug 2013
- tamoxifen / Generic mfg., exemestane / Generic mfg.
Enrollment closed, HEOR: Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=58, Active, not recruiting, Sponsor: University of Michigan
Initiation date: Jan 2013 --> Aug 2013 Recruiting --> Active, not recruiting
- | New P4 trial: Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (clinicaltrials.gov) - Jan 27, 2013
P4, N=240, Recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Trial termination, Metastases: Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 22, 2013
P1, N=30, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated; Administratively complete.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: TEARS: Tolerance and Efficacy of Rituximab in Sjogren's Disease (clinicaltrials.gov) - Jan 20, 2013
P2/3, N=122, Completed, Sponsor: University Hospital, Brest
Completed --> Terminated; Administratively complete. Active, not recruiting --> Completed
- gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 10, 2013
P=N/A, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Anti-CD20 Antibody Therapy for Sjogren's Syndrome (clinicaltrials.gov) - Dec 20, 2012
P1, N=12, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Clinical: The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study (clinicaltrials.gov) - Dec 19, 2012
P=N/A, N=38, Completed, Sponsor: University of Sao Paulo General Hospital
- | gefitinib / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer (clinicaltrials.gov) - Dec 18, 2012
P3, N=330, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=10, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children (clinicaltrials.gov) - Oct 22, 2012
P1, N=300, Completed, Sponsor: Chinese Academy of Medical Sciences
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
New P2 trial, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 30, 2012
P2, N=76, Recruiting, Sponsor: National Cancer Institute (NCI)